Conference Call with Anthem Biosciences Management and Analysts on Q3FY26 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Anthem Biosciences announced Q3FY26 results Consolidated Revenue from Operations was Rs 4,232 million for the quarter. CRDMO business delivered Rs 3,332 million revenues. Specialty Ingredients delivered Rs 899 million revenues. EBITDA was Rs 1,907 million, with EBITDA margins at 41.8%. EBITDA for Q3FY26 includes Other Income of Rs 335 million (Q3FY25: Rs 244 million). Other Operating Income on account of forex gain (net) and RoDTEP incentives is Rs 64 million (Q3FY25: Rs 98 million). Financial and other Non-Operating Income is Rs 271 million (Q3FY25: Rs 146 million). PBT before exceptions items was Rs 1,558 million. Exceptional item on account of new labour code impact was Rs 254 million. PAT (Profit After Tax) was Rs 928 million, with PAT margins at 20.3%. Ajay Bhardwaj, Chairman, MD & CEO, Anthem Biosciences, said: “Our 9MFY26 performance has shown steady progress in revenue terms and with improving margin profile our EBITDA has grown at 23% and PBT before exceptional items has grown around 20%. Our quarterly revenue performance was influenced by the higher base of the same quarter last year, although the margin improvement neutralised the revenue shortfall. The underlying demand remains robust, with our historically strongest quarter still ahead, we are confident of delivering a strong finish to the financial year.” Result PDF